539 related articles for article (PubMed ID: 34187307)
1. m6A RNA methylation regulators were associated with the malignancy and prognosis of ovarian cancer.
Zhang C; Liu J; Guo H; Hong D; Ji J; Zhang Q; Guan Q; Ren Q
Bioengineered; 2021 Dec; 12(1):3159-3176. PubMed ID: 34187307
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
Jiao J; Jiang L; Luo Y
Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
[TBL] [Abstract][Full Text] [Related]
4. Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.
Deng M; Fang L; Li SH; Zhao RC; Mei J; Zou JW; Wei W; Guo RP
Mutagenesis; 2021 Oct; 36(5):369-379. PubMed ID: 34467992
[TBL] [Abstract][Full Text] [Related]
5. Gene Signatures and Prognostic Values of m6A RNA Methylation Regulators in Ovarian Cancer.
Han X; Liu J; Cheng G; Cui S
Cancer Control; 2020; 27(1):1073274820960460. PubMed ID: 32951457
[TBL] [Abstract][Full Text] [Related]
6. The methylation modification of m6A regulators contributes to the prognosis of ovarian cancer.
Zhu W; Zhao L; Kong B; Liu Y; Zou X; Han T; Shi Y
Ann Transl Med; 2022 Jan; 10(2):59. PubMed ID: 35282121
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
[TBL] [Abstract][Full Text] [Related]
8. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
9. A Risk Score Model Incorporating Three m6A RNA Methylation Regulators and a Related Network of miRNAs-m6A Regulators-m6A Target Genes to Predict the Prognosis of Patients With Ovarian Cancer.
Li Q; Ren CC; Chen YN; Yang L; Zhang F; Wang BJ; Zhu YH; Li FY; Yang J; Zhang ZA
Front Cell Dev Biol; 2021; 9():703969. PubMed ID: 34631700
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
12. The N6-Methyladenosine- (m6A-) Associated Genes Act as Strong Key Biomarkers for the Prognosis of Pancreatic Adenocarcinoma.
Li F; Zhang P
Comput Math Methods Med; 2021; 2021():8715823. PubMed ID: 34840598
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
16. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
Miao C; Fang X; Chen Y; Zhao Y; Guo Q
Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
[TBL] [Abstract][Full Text] [Related]
17. m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.
Chen M; Nie ZY; Wen XH; Gao YH; Cao H; Zhang SF
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31808521
[TBL] [Abstract][Full Text] [Related]
18. Construction and Validation of an m6A RNA Methylation Regulators-Based Prognostic Signature for Esophageal Cancer.
Xu LC; Pan JX; Pan HD
Cancer Manag Res; 2020; 12():5385-5394. PubMed ID: 32753956
[TBL] [Abstract][Full Text] [Related]
19. N6-methyladenosine methylation regulator FTO promotes oxidative stress and induces cell apoptosis in ovarian cancer.
Wu J; Wang X; Li X
Epigenomics; 2022 Dec; 14(23):1509-1522. PubMed ID: 36815224
[TBL] [Abstract][Full Text] [Related]
20. The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer.
Wang J; Lin H; Zhou M; Xiang Q; Deng Y; Luo L; Liu Y; Zhu Z; Zhao Z
Future Oncol; 2020 Oct; 16(30):2421-2432. PubMed ID: 32687727
[No Abstract] [Full Text] [Related]
[Next] [New Search]
